Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a chronic disease caused by transthyretin (TTR) tetramer destabilization and subsequent TTR amyloid fibril deposition in the myocardium, leading to progressive heart failure (HF), impaired quality of life, hospitalization, and death.1,2
Authors
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Ronald Witteles (ORCID: https://orcid.org/0000-0002-3043-1472)
- Suresh Siddhanti
- Alan X. Ji
- Leonid Katz
- Mathew S. Maurer (ORCID: https://orcid.org/0000-0001-5400-5008)
- Daniel Jacoby (ORCID: https://orcid.org/0000-0002-9182-275X)
- Ahmad Masri (ORCID: https://orcid.org/0000-0002-6390-6526)
- Daniel Philip Judge (ORCID: https://orcid.org/0000-0002-3407-0248)
- Uma Sinha
- Jonathan C. Fox
- Jing Du (ORCID: https://orcid.org/0009-0007-0350-2734)
- Martha Grogan
- Mandar A. Aras
- Paul Wong
Institutions
- Northwestern University (US)
- Medical University of South Carolina (US)
- Oregon Health & Science University (US)
- Columbia University Irving Medical Center (US)
- Yale Cancer Center (US)
- University Medical Center (US)
- Yale University (US)
- University Hospital and Clinics (US)
- Mayo Clinic in Arizona (US)
- BridgeBio (United States) (US)
- Bridge Pharma (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of Cardiac Failure
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1016/j.cardfail.2025.03.017
- Citations
- 5
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Edwards Lifesciences
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Cytokinetics
- Prothena
- ReCor Medical
- MyoKardia
- Impulse Dynamics
- Novo Nordisk
- National Heart, Lung, and Blood Institute
- Janssen Pharmaceuticals